NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $201,974 | -23.2% | 10,511 | +1.5% | 0.00% | – |
| Q2 2023 | $263,068 | -31.4% | 10,351 | -2.5% | 0.00% | -100.0% |
| Q1 2023 | $383,677 | -7.8% | 10,615 | +1.3% | 0.00% | 0.0% |
| Q4 2022 | $416,000 | +22.4% | 10,483 | +43.2% | 0.00% | 0.0% |
| Q3 2022 | $340,000 | -25.8% | 7,322 | -29.8% | 0.00% | 0.0% |
| Q2 2022 | $458,000 | -7.7% | 10,434 | +51.8% | 0.00% | 0.0% |
| Q1 2022 | $496,000 | -12.1% | 6,872 | -1.2% | 0.00% | 0.0% |
| Q4 2021 | $564,000 | -6.6% | 6,954 | +33.8% | 0.00% | 0.0% |
| Q3 2021 | $604,000 | -37.3% | 5,198 | -10.6% | 0.00% | -50.0% |
| Q2 2021 | $964,000 | +44.1% | 5,816 | +21.2% | 0.00% | 0.0% |
| Q1 2021 | $669,000 | -7.7% | 4,797 | +14.6% | 0.00% | 0.0% |
| Q4 2020 | $725,000 | +7.6% | 4,187 | -13.5% | 0.00% | 0.0% |
| Q3 2020 | $674,000 | +41.3% | 4,838 | +21.6% | 0.00% | 0.0% |
| Q2 2020 | $477,000 | +59.0% | 3,980 | +32.4% | 0.00% | +100.0% |
| Q1 2020 | $300,000 | – | 3,007 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |